Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aerpio Pharmaceuticals Inc (NQ: ARPO )

1.350 USD -0.030 (-2.17%)
Official Closing Price Updated: 7:57 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aerpio Pharmaceuticals Inc

< Previous 1 2 Next >
Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial
From GlobeNewswire News Releases
Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial
From GlobeNewswire News Releases
Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial
From GlobeNewswire News Releases
Thinking about buying stock in Pfizer, Ampio Pharmaceuticals, Aerpio Pharmaceuticals, Electrameccanica Vehicles, or United Airlines?
InvestorsObserver issues critical PriceWatch Alerts for PFE, AMPE, ARPO, SOLO, and UAL. 
From PR Newswire
Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Aerpio Hosting Key Opinion Leader Call on New Therapeutic Agents for COVID-19
Call Taking Place on Thursday, November 12th @ 11amET 
From GlobeNewswire News Releases
Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10
From GlobeNewswire News Releases
Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19
From GlobeNewswire News Releases
Aravive Appoints Michael W. Rogers to Board of Directors
Strengthens Advisory Team with Industry Veteran as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer (PROC) 
From GlobeNewswire News Releases
Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial
Topline Data Expected 4Q 2020 
From GlobeNewswire News Releases
Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients
From GlobeNewswire News Releases
Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients
Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today dosing of the first patient with razuprotafib in the I-SPY COVID Trial... 
From PR Newswire
Thinking about buying stock in Navidea Biopharmaceuticals, CleanSpark Inc, Aerpio Pharmaceuticals, Hertz Global Holdings, or Walt Disney?
InvestorsObserver issues critical PriceWatch Alerts for NAVB, CLSK, ARPO, HTZ, and DIS. 
From PR Newswire
Aerpio Reports Second Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Bullish Stocks Trading Above 20Days Moving Average: $SYNC $CNTY $ARPO
Tags The Market Signal
From The Market Signal
Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12
From GlobeNewswire News Releases
Thinking about buying stock in Sorrento Therapeutics, Aerpio Pharmaceuticals, Horizon Therapeutics, Riot Blockchain, or Royal Caribbean Cruises?
InvestorsObserver issues critical PriceWatch Alerts for SRNE, ARPO, HZNP, RIOT, and RCL. 
From PR Newswire
Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19
From GlobeNewswire News Releases
Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial
From GlobeNewswire News Releases
Aerpio Announces Change to Virtual Format for its 2020 Annual Meeting of Stockholders due to COVID-19
From GlobeNewswire News Releases
Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma
From GlobeNewswire News Releases
Thinking about buying stock in Aerpio Pharmaceuticals, Axcella Health, General Electric, Zomedica Pharmaceuticals, or Avis Budget Group?
InvestorsObserver issues critical PriceWatch Alerts for ARPO, AXLA, GE, ZOM, and CAR. 
From PR Newswire
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Sy
From GlobeNewswire News Releases
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Sy
Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has been reached to evaluate razuprotafib in a new... 
From PR Newswire
Thinking about buying stock in J C Penney, Aerpio Pharmaceuticals, Norwegian Cruise Line, Marathon Oil Corp, or Microvision?
InvestorsObserver issues critical PriceWatch Alerts for JCP, ARPO, NCLH, MRO, and MVIS. 
From PR Newswire
Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)
Aerpio Received an Immediate Payment of $15 million 
From GlobeNewswire News Releases
Aerpio Reports First Quarter 2020 Financial Results and Provides Business Update
Razuprotafib (formerly known as AKB-9778) Phase 2 Open Angle Glaucoma Trial on Track for Third Quarter Start 
From GlobeNewswire News Releases
Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Aerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020
From GlobeNewswire News Releases
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.